1.A longitudinal change of ODI and APDI on three facial growth patterns in Koreans with normal occlusion.
Sun Reong LEE ; Kyung Duk PARK ; Hee Moon KYUNG ; Jae Hyun SUNG
Korean Journal of Orthodontics 1996;26(5):557-568
The purpose of this study was to analyze the growth changes of ODI and APDI with age on the three facial growth patterns. The biennial serial cephalometric radiographs of 19 male and 14 famale samples with normal occlusion during 10 years were used in this study. The samples were divided into three groups - drop type, neutral type, forward type - by the total change of the Y-axis during the periods of the study. The findings in this investigation indicated the following: 1. The mean values and standard deviations of each age group in each facial type of male and famale were obtained. 2. The difference of ODI and APDI among the 3 facial types was not significant through all observed ages(P>0.05). The size of ODI appeared large consistently in order of the drop, neutral, and forward type in both male and female through all observed ages. 3. The ODI and APDI were maintained without any changes with age during the periods of the study(P>0.05). 4. In correlation analysis between the total change of the Y-axis and 6 measurements, the AB plane angle and facial angle showed correlation in both male and female(P<0.05), the APDI in only female(P<0.001), but the ODI not appeared correlation in either male or female(P>0.05).
Female
;
Humans
;
Longitudinal Studies
;
Male
2.The Effects of Esmolol or Labetalol on Hemodynamic and Catecholamine Level in Endotracheal Intubation.
Jang Woon YUN ; Jung Sun HAN ; Sang Yeol LEE ; Chul Reong HUR ; Young Joo LEE ; Young Suk LEE
Korean Journal of Anesthesiology 1998;34(1):77-85
BACKGROUND: Sympathetic blocking agent, esmolol (selective beta 1 blocker) or labetalol ( alpha and beta blocker) would prevent the hypertension and tachycardia from endotracheal intubation. We have carried out the study to see the effects of esmolol or labetalol on the blood pressure, heart rate, rate pressure product and plasma catecolamines during the endotracheal intubation. METHODS: Thirty-three ASA physical status 1 or 2 adult patients were allocated into three groups; Group I:control (n=10), Group II:esmolol (n=11) and Group III: labetalol (n=12). In Group I, 2 ml of normal saline, in Group II, 1 mg/kg of esmolol, and in Group III, 0.2 mg/kg of labetalol were given 3, 2 and 4 minutes before endotracheal intubation. Blood pressure and heart rate were measured after arrival at the operating room, before endotracheal intubation and after endotracheal intubation at 15, 60, 120, 180 and 300 seconds interval under the inhalation anesthesia (enflurane-N2O-O2). Rate-pressure product was calculated from the heart rate and systolic blood pressure (RPP = heart rate x systolic blood pressure). The plasma cathecolamines, dopamine, norepinephrine and epinephrine, were measured before intubation as a baseline value and 2 minute after intubation. RESULTS: Systolic blood pressure, rate-pressure product and heart rate were significantly lower in esmolol and labetalol groups than in control group after intubation ( p<0.05). Esmolol reduced the heart rate and the rate-pressure product than labetalol, but statistically there were no significance (P > 0.05). Plasma level of dopamine, norepinephrine and epinephrine showed higher values after intubation in all three groups ( p<0.05). But there were no difference among groups (P>0.05). The side effects of esmolol and labetalol did not appear at all. CONCLUSION: 1 mg/kg of esmolol given 2 min before intubation or 0.2 mg/kg of labetalol given 4 min before intubation reduce increasing of blood pressure and heart rate, caused by adnergic response following endotracheal intubation, significantly. The reason is that esmolol and labetalol do not decrease release of catecholamines but attenuate responses of elevated catecholamines following endotracheal intubation.
Adult
;
Anesthesia, Inhalation
;
Blood Pressure
;
Catecholamines
;
Dopamine
;
Epinephrine
;
Heart Rate
;
Hemodynamics*
;
Humans
;
Hypertension
;
Intubation
;
Intubation, Intratracheal*
;
Labetalol*
;
Norepinephrine
;
Operating Rooms
;
Plasma
;
Tachycardia